{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:21:08Z","timestamp":1792794068926,"version":"4.5.0"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,1,29]],"date-time":"2019-01-29T00:00:00Z","timestamp":1548720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1038\/s41375-019-0378-z","type":"journal-article","created":{"date-parts":[[2019,1,29]],"date-time":"2019-01-29T09:04:46Z","timestamp":1548752686000},"page":"1851-1867","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":127,"title":["European recommendations and quality assurance for cytogenomic analysis of haematological neoplasms"],"prefix":"10.1038","volume":"33","author":[{"given":"K. A.","family":"Rack","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"van den Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Haferlach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. B.","family":"Beverloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Espinet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Foot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Jeffries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Schoumans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Talley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Telford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Stioui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Zemanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. J.","family":"Hastings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,29]]},"reference":[{"key":"378_CR1","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC; 2017."},{"key":"378_CR2","unstructured":"Mitelman F, Johansson B, Mertens F. Mitelman database of chromosome aberrations and gene fusions in cancer. 2018. http:\/\/cgap.nci.nih.gov\/Chromosomes\/Mitelman"},{"key":"378_CR3","unstructured":"Hastings R, Howell R, Betts D, Porter S, Haferlach C, Dastugue N, et al. Guidelines and quality assurance for acquired cytogenetics. European cytogeneticists association newsletter No. 31. 2013. https:\/\/www.e-c-a.eu\/en\/NEWSLETTER.html ."},{"key":"378_CR4","unstructured":"ISCN: an international system for human cytogenomic nomenclature 2016. In: McGowan-Jordan J, Simons A, Schmid M, editors. Basel: S. Karger; 2016."},{"key":"378_CR5","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/nrg1692","volume":"6","author":"MR Speicher","year":"2005","unstructured":"Speicher MR, Carter NP. The new cytogenetics: blurring the boundaries with molecular biology. Nat Rev Genet. 2005;6:782\u201392.","journal-title":"Nat Rev Genet"},{"key":"378_CR6","unstructured":"ISO 15189:2012 Medical laboratories-requirements for quality and competence. https:\/\/iso.org\/"},{"key":"378_CR7","unstructured":"European Leukaemia Network http:\/\/www.leukemia-net.org\/content\/home\/index_eng.html"},{"key":"378_CR8","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.leukres.2012.03.013","volume":"36","author":"AM Cherry","year":"2012","unstructured":"Cherry AM, Slovak ML, Campbell LJ, Chun K, Eclache V, Haase D, et al. Will a peripheral blood (PB) sample yield the same diagnostic and prognostic cytogenetic data as the concomitant bone marrow (BM) in myelodysplasia? Leuk Res. 2012;36:832\u201340.","journal-title":"Leuk Res"},{"key":"378_CR9","doi-asserted-by":"crossref","unstructured":"Nyla A Heerema. Cytogenetic analysis of hematologic malignant diseases. In: Marilyn S Arsham, Margaret J. Barch, Helen J. Lawce, editors. The AGT Cytogenetics Laboratory Manual. 4th ed. Hoboken, New Jersey:Wiley-Blackwell; 2017; p. 499\u2013575.","DOI":"10.1002\/9781119061199.ch11"},{"key":"378_CR10","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/gcc.20450","volume":"46","author":"VL Earle","year":"2007","unstructured":"Earle VL, Ross F, Fisher A, Strike P, Berrington S, Chiecchio L, et al. Haemopoietic growth factors significantly improve the mitotic index and chromosome quality in cytogenetic cultures of myeloid neoplasia. Genes Chromosomes Cancer. 2007;46:670\u20134.","journal-title":"Genes Chromosomes Cancer"},{"key":"378_CR11","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/gcc.20433","volume":"46","author":"C Haferlach","year":"2007","unstructured":"Haferlach C, Rieder H, Lillington DM, Dastugue N, Hagemeijer A, Harbott J, et al. Proposals for standardized protocols for cytogenetic analyses of acute leukemias, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myeloproliferative disorders, and myelodysplastic syndromes. Genes Chromosomes Cancer. 2007;46:494\u20139.","journal-title":"Genes Chromosomes Cancer"},{"key":"378_CR12","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1182\/blood.V75.11.2097.2097","volume":"75","author":"I Touw","year":"1991","unstructured":"Touw I, Pouwels K, van Agthoven T, van Gurp R, Budel L, Hoogerbrugge H, et al. Interleukin-7 is a growth factor of precursor B and T acute lmphoblastic leukemia. Blood. 1991;75:2097\u2013101.","journal-title":"Blood"},{"key":"378_CR13","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/sj.leu.2402389","volume":"16","author":"T Decker","year":"2002","unstructured":"Decker T, Schneller F, Hipp S, Miething C, Jahn T, Duyster J, et al. Cell cycle progression of chronic lymphocytic leukemia cells is controlled by cyclin D2, cyclin D3, cyclin-dependent kinase (cdk)4 and the cdk inhibitor p27. Leukemia. 2002;16:327\u201334.","journal-title":"Leukemia"},{"key":"378_CR14","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1182\/blood-2006-02-005322","volume":"108","author":"F Dicker","year":"2006","unstructured":"Dicker F, Schnittger S, Haferlach T, Kern W, Schoch C. Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: a study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression. Blood. 2006;108:3152\u201360.","journal-title":"Blood"},{"key":"378_CR15","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1038\/sj.leu.2404935","volume":"21","author":"C Haferlach","year":"2007","unstructured":"Haferlach C, Dicker F, Schnittger S, Kern W, Haferlach T. Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgVH status and immunophenotyping. Leukemia. 2007;21:2442\u201351.","journal-title":"Leukemia"},{"key":"378_CR16","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.cancergencyto.2010.07.128","volume":"203","author":"NA Heerema","year":"2010","unstructured":"Heerema NA, Byrd JC, Dal Cin PS, Dell\u2019 Aquila ML, Koduru PR, Aviram A, et al. Stimulation of chronic lymphocytic leukemia cells with CpG oligodeoxynucleotide gives consistent karyotypic results among laboratories: a CLL Research Consortium(CRC) Study. Cancer, Genet Cytogenet. 2010;203:134\u201340.","journal-title":"Cancer, Genet Cytogenet"},{"key":"378_CR17","first-page":"94","volume":"29","author":"EB Hook","year":"1977","unstructured":"Hook EB. Exclusion of chromosomal mosaicism: tables of 90%, 95% and 99% confidence limits and comments on use. Am J Hum Genet. 1977;29:94\u201397.","journal-title":"Am J Hum Genet"},{"key":"378_CR18","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0037-1963(00)90013-1","volume":"37","author":"A Gozzetti","year":"2000","unstructured":"Gozzetti A, Le Beau MM. Fluorescence in situ hybridization: uses and limitations. Semin Hematol. 2000;37:320\u201333.","journal-title":"Semin Hematol"},{"key":"378_CR19","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/nprot.2007.534","volume":"3","author":"B Summersgil","year":"2008","unstructured":"Summersgil B, Clark J, Shipley J. Fluorescence and chromogenic in situ hybridization to detect genetic aberrations in formalin-fixed paraffin embedded material, including tissue microarrays. Nat Protoc. 2008;3:220\u201334.","journal-title":"Nat Protoc"},{"key":"378_CR20","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000108305","volume":"118","author":"MG Tibiletti","year":"2007","unstructured":"Tibiletti MG. Interphase FISH as a new tool in tumor pathology. Cytogenet Genome Res. 2007;118:229\u201336.","journal-title":"Cytogenet Genome Res"},{"key":"378_CR21","unstructured":"Tibiletti MG, Vanni R. FISH on Histological sections of solid tumours: ECA recommendations. ECA Newsletter No. 27, 2011. https:\/\/www.e-c-a.eu\/en\/NEWSLETTER.html ."},{"key":"378_CR22","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/gcc.22350","volume":"55","author":"J Schoumans","year":"2016","unstructured":"Schoumans J, Suela J, Hastings R, Muehlematter D, Rack K, van den Berg E, et al. Guidelines for genomic array analysis in acquired haematological neoplastic disorders. Genes Chromosomes Cancer. 2016;55:480\u201391.","journal-title":"Genes Chromosomes Cancer"},{"key":"378_CR23","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1038\/s41375-018-0037-9","volume":"32","author":"N Bolli","year":"2018","unstructured":"Bolli N, Biancon G, Moarii M, Gimondi S, Li Y, de Philippis C, et al. Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. Leukemia. 2018;32:2604\u201316.","journal-title":"Leukemia"},{"key":"378_CR24","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Blood. 2013;122:872\u201384.","journal-title":"Blood"},{"issue":"Suppl 2","key":"378_CR25","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1007\/s00277-015-2322-2","volume":"94","author":"M Baccarani","year":"2015","unstructured":"Baccarani M, Castagnetti F, Gugliotta G, Rosti G. A review of the European LeukemiaNet recommendations for the management of CML. Ann Hematol. 2015;94(Suppl 2):S141\u20137.","journal-title":"Ann Hematol"},{"key":"378_CR26","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1182\/blood-2008-06-162388","volume":"112","author":"D Marin","year":"2008","unstructured":"Marin D, Milojkovic D, Olavarria E, Khorashad JS, de Lavallade H, Reid AG, et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood. 2008;112:4437\u201344.","journal-title":"Blood"},{"key":"378_CR27","doi-asserted-by":"crossref","first-page":"6760","DOI":"10.1182\/blood-2011-08-373902","volume":"118","author":"A Fabarius","year":"2011","unstructured":"Fabarius A, Leitner A, Hochhaus A, M\u00fcller MC, Hanfstein B, Haferlach C, et al. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood. 2011;118:6760\u20138.","journal-title":"Blood"},{"key":"378_CR28","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1080\/10428190802492415","volume":"50","author":"F Palandri","year":"2009","unstructured":"Palandri F, Testoni N, Luatti S, Marzocchi G, Baldazzi C, Stacchini M, et al. Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results. Leuk Lymphoma. 2009;50:114\u20138.","journal-title":"Leuk Lymphoma"},{"key":"378_CR29","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1182\/blood-2002-09-2790","volume":"101","author":"JE Cortes","year":"2003","unstructured":"Cortes JE, Talpaz M, Giles F, O\u2019Brien S, Rios MB, Shan J, et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood. 2003;101:3794\u20133800.","journal-title":"Blood"},{"key":"378_CR30","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1182\/blood-2016-01-690230","volume":"127","author":"W Wang","year":"2016","unstructured":"Wang W, Cortes JE, Tang G, Khoury JD, Wang S, Bueso-Ramos CE, et al. Risk stratification of chromosomal abnormalities in chronic leukemia in the era of tyrosine kinase inhibitor therapy. Blood. 2016;127:2742\u201350.","journal-title":"Blood"},{"key":"378_CR31","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","volume":"27","author":"M Baccarani","year":"2009","unstructured":"Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27:6041\u201351.","journal-title":"J Clin Oncol"},{"key":"378_CR32","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jmoldx.2013.07.002","volume":"15","author":"JZ Gong","year":"2013","unstructured":"Gong JZ, Cook JR, Greiner TC, Hedvat C, Hill CE, Lim MS, et al. Laboratory practice guidelines for detecting and reporting JAK2 and MPL mutations in myeloproliferative neoplasms: a report of the association for molecular pathology. J Mol Diagn. 2013;15:733\u201344.","journal-title":"J Mol Diagn"},{"key":"378_CR33","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1002\/ajh.24578","volume":"91","author":"D Xia","year":"2016","unstructured":"Xia D, Hassejian RP. Molecular testing for JAK2, MPL, and CALR in myeloproliferative neoplasms. Am J Hematol. 2016;91:1277\u201380.","journal-title":"Am J Hematol"},{"key":"378_CR34","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3324\/haematol.2013.091454","volume":"99","author":"M Brecqueville","year":"2014","unstructured":"Brecqueville M, Rey J, Devillier R, Guille A, Gillet R, Ad\u00e9laide J, et al. Array comparative genomic hybridization and sequencing of 23 genes in 80 patients with myelofibrosis at chronic or acute phase. Haematologica. 2014;99:37\u201345.","journal-title":"Haematologica"},{"key":"378_CR35","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/leu.2010.234","volume":"25","author":"D Caramazza","year":"2011","unstructured":"Caramazza D, Begna KH, Gangat N, Vaidya R, Siragusa S, Van Dyke DL, et al. Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. Leukemia. 2011;25:82\u201388.","journal-title":"Leukemia"},{"key":"378_CR36","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood-2009-08-240135","volume":"115","author":"K Hussein","year":"2010","unstructured":"Hussein K, Pardanani AD, Van Dyke DL, Hanson CA, Tefferi A. International Prognostic Scoring System\u2013independent cytogenetic risk categorization in primary myelofibrosis. Blood. 2010;115:496\u20139.","journal-title":"Blood"},{"key":"378_CR37","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1182\/blood-2008-09-178541","volume":"113","author":"CS Tam","year":"2009","unstructured":"Tam CS, Abruzzo LV, Lin KI, Cortes J, Lynn A, Keating MJ, et al. The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course. Blood. 2009;113:4171\u20138.","journal-title":"Blood"},{"key":"378_CR38","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/s41375-018-0018-z","volume":"32","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Nicolosi M, Mudireddy M, Lasho TL, Gangat N, Begna KH, et al. Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients. Leukemia. 2018;32:1189\u201399.","journal-title":"Leukemia"},{"key":"378_CR39","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1365-2141.2012.09179.x","volume":"158","author":"JT Reilly","year":"2012","unstructured":"Reilly JT, McMullin FM, Beer PA, Butt N, Conneally E, Duncombe A, et al. Guideline for the diagnosis and management of myelofibrosis. Br J Haematol. 2012;158:453\u201371.","journal-title":"Br J Haematol"},{"key":"378_CR40","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/bjh.14488","volume":"176","author":"NM Butt","year":"2017","unstructured":"Butt NM, Lambert J, Ali S, Beer PA, Cross NCP, Duncombe A, et al. Guideline for the investigation and management of eosinophilia. Br J Haematol. 2017;176:553\u201372.","journal-title":"Br J Haematol"},{"key":"378_CR41","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1182\/blood-2013-03-492884","volume":"122","author":"L Malcovati","year":"2013","unstructured":"Malcovati L, Hellstr\u00f6m-Lindberg E, Bowen D, Ad\u00e8s L, Cermak J, del Ca\u00f1izo C, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood. 2013;122:2943\u201364.","journal-title":"Blood"},{"key":"378_CR42","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","volume":"120","author":"PL Greenberg","year":"2012","unstructured":"Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sol\u00e9 F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454\u201365.","journal-title":"Blood"},{"key":"378_CR43","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1200\/JCO.2011.35.6394","volume":"30","author":"J Schanz","year":"2012","unstructured":"Schanz J, T\u00fcchler H, Sol\u00e9 F, Mallo M, Lu\u00f1o E, Cervera J, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012;30:820\u20139.","journal-title":"J Clin Oncol"},{"key":"378_CR44","doi-asserted-by":"crossref","first-page":"6601","DOI":"10.1182\/blood-2011-07-365189","volume":"118","author":"T Katagiri","year":"2011","unstructured":"Katagiri T, Sato-Otsubo A, Kashiwase K, Morishima S, Sato Y, Mori Y. et al.Japan Marrow Donor Program Frequent loss of HLA alleles associated with copy number-neutral 6p LOH in acquired aplastic anemia. Blood. 2011;118:6601\u20139.","journal-title":"Blood"},{"key":"378_CR45","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1182\/blood-2012-08-452938","volume":"121","author":"E Such","year":"2013","unstructured":"Such E, Germing U, Malcovati L, Cervera J, Kuendgen A, Della Porta MG, et al. Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood. 2013;121:3005\u201315.","journal-title":"Blood"},{"key":"378_CR46","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ejmg.2016.01.006","volume":"59","author":"CJ Harrison","year":"2016","unstructured":"Harrison CJ, Schwab C. Constitutional abnormalities of chromosome 21 predispose to iAMP21-acute lymphoblastic leukaemia. Eur J Med Genet. 2016;59:162\u20135.","journal-title":"Eur J Med Genet"},{"key":"378_CR47","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424\u201347.","journal-title":"Blood"},{"key":"378_CR48","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"D Grimwade","year":"2017","unstructured":"Grimwade D, Ivey A, Huntly BKJ. Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. Blood. 2017;129:424\u201347.","journal-title":"Blood"},{"key":"378_CR49","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","volume":"116","author":"D Grimwade","year":"2010","unstructured":"Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, et al. Refinement of cytogenetic classification in AML: determination of prognostic significance of rare recurring chromosomal abnormalities amongst 5635 younger adults treated in the UK MRC trials. Blood. 2010;116:354\u201365.","journal-title":"Blood"},{"key":"378_CR50","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/gcc.22100","volume":"52","author":"S Akiki","year":"2013","unstructured":"Akiki S, Dyer SA, Grimwade D, Ivey A, Abou-Zeid N, Borrow J, et al. NUP98-NSD1 fusion in association with FLT3-ITD mutations identifies a prognostically relevant subgroup of pediatric acute myeloid leukemia patients suitable for monitoring by realtime quantitative PCR. Genes Chromosomes Cancer. 2013;52:1053\u201364.","journal-title":"Genes Chromosomes Cancer"},{"key":"378_CR51","doi-asserted-by":"crossref","first-page":"3645","DOI":"10.1182\/blood-2011-04-346643","volume":"118","author":"IH Hollink","year":"2011","unstructured":"Hollink IH, van den Heuvel-Eibrink MM, Arentsen-Peters ST, Pratcorona M, Abbas S, Kuipers JE, et al. NUP98\/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern. Blood. 2011;118:3645\u201356.","journal-title":"Blood"},{"key":"378_CR52","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/gcc.22064","volume":"52","author":"N Shiba","year":"2013","unstructured":"Shiba N, Ichikawa H, Taki T, Park ML, Jo A, Mitani S, et al. NUP98-NSD1 gene fusion and its related gene expression signature are strongly associated with a poor prognosis in pediatric acute myeloid leukemia. Genes Chromosomes Cancer. 2013;52:683\u201393.","journal-title":"Genes Chromosomes Cancer"},{"key":"378_CR53","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/gcc.20335","volume":"45","author":"AR Bergh von","year":"2006","unstructured":"von Bergh AR, van Drunen E, van Wering ER, van Zutven LJ, Hainmann I, L\u00f6nnerholm G, et al. High incidence of t(7;12)(q36; p13) in infant AML but not infant ALL, with a dismal outcome and ectopic expression of HLXB9. Genes Chromosomes Cancer. 2006;45:731\u20139.","journal-title":"Genes Chromosomes Cancer"},{"key":"378_CR54","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/1098-2264(2000)9999:9999<::AID-GCC1039>3.0.CO;2-9","volume":"29","author":"S Tosi","year":"2000","unstructured":"Tosi S, Harbott J, Teigler-Schegel A, Haas OA, Pirc-Danoewinata H, Harrison CJ, et al. t(7;12)(q36; p13), a new recurrent translocation involving ETV6 in infant leukemia. Genes Chromosomes Cancer. 2000;29:325\u201332.","journal-title":"Genes Chromosomes Cancer"},{"key":"378_CR55","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ccr.2012.10.007","volume":"22","author":"TA Gruber","year":"2012","unstructured":"Gruber TA, Larson Gedman A, Zhang J, Koss CS, Marada S, Ta HQ, et al. An Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia. Cancer Cell. 2012;22:683\u201397.","journal-title":"Cancer Cell"},{"key":"378_CR56","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1182\/blood-2012-11-469825","volume":"121","author":"R Masetti","year":"2013","unstructured":"Masetti R, Pigazzi M, Togni M, Astolfi A, Indio V, Manara E, et al. CBFA2T3-GLIS2 fusion transcript is a novel common fusion in pediatric, cytogenetically normal AML, not restricted to FAB M7 subgroup. Blood. 2013;121:3469\u201372.","journal-title":"Blood"},{"key":"378_CR57","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1365-2141.2010.08314.x","volume":"151","author":"CJ Harrison","year":"2010","unstructured":"Harrison CJ, Haas O, Harbott J, Biondi A, Stanulla M, Trka J, et al. Detection of prognostically relevant genetic abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: recommendations from the Biology and Diagnosis Committee of the International Berlin-Frankfurt-Munster study group. Br J Haematol. 2010;151:132\u201314.","journal-title":"Br J Haematol"},{"key":"378_CR58","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.blre.2012.01.001","volume":"26","author":"AV Moorman","year":"2012","unstructured":"Moorman AV. The clinical relevance of chromosomal and genomic abnormalities in B-cell precursor acute lymphoblastic leukaemia. Blood Rev. 2012;26:123\u201335.","journal-title":"Blood Rev"},{"key":"378_CR59","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S1470-2045(10)70066-8","volume":"11","author":"AV Moorman","year":"2010","unstructured":"Moorman AV, Ensor HM, Richards SM, Chilton L, Schwab C, Kinsey SE, et al. Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97\/99 randomised trial. Lancet Oncol. 2010;11:429\u201338.","journal-title":"Lancet Oncol"},{"issue":"suppl_5","key":"378_CR60","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/annonc\/mdw025","volume":"27","author":"D Hoelzer","year":"2016","unstructured":"Hoelzer D, Bassan R, Dombret H, Fielding A, Ribera JM, Buske C. Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl_5):69\u201382.","journal-title":"Ann Oncol"},{"key":"378_CR61","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/ng.2532","volume":"45","author":"L Homfeldt","year":"2013","unstructured":"Homfeldt L, Wei L, Diaz-Flores E, Walsh M, Zhang J, Ding L, et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet. 2013;45:242\u201352.","journal-title":"Nat Genet"},{"key":"378_CR62","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1182\/blood-2003-04-1128","volume":"102","author":"AV Moorman","year":"2003","unstructured":"Moorman AV, Richards SM, Martineau M, Cheung KL, Robinson HM, Jalali GR. et al.United Kingdom Medical Research Council\u2019s Childhood Leukemia Working Party Outcome heterogeneity in childhood high-hyperdiploid acute lymphoblastic leukemia. Blood. 2003;102:2756\u201362.","journal-title":"Blood"},{"key":"378_CR63","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1182\/blood-2017-06-743252","volume":"130","author":"SK Tasian","year":"2017","unstructured":"Tasian SK, Loh ML, Hunger SP. Philadelphia chromosome\u2013like acute lymphoblastic leukemia. Blood. 2017;130:2064\u201372.","journal-title":"Blood"},{"key":"378_CR64","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1038\/sj.leu.2404302","volume":"20","author":"C Graux","year":"2006","unstructured":"Graux C, Cools J, Michaux L, Vandenberghe P, Hagemeijer A. Cytogenetics and molecular genetics of T-cell acute lymphoblastic leukemia: from thymocyte to lymphoblast. Leukemia. 2006;20:1496\u2013510.","journal-title":"Leukemia"},{"key":"378_CR65","doi-asserted-by":"crossref","unstructured":"Heim S, Mitelman F. Cancer Cytogenetics. 4th Ed. UK: Wiley-Blackwell Press; 2015.","DOI":"10.1002\/9781118795569"},{"key":"378_CR66","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1038\/sj.leu.2403877","volume":"19","author":"K Stergianou","year":"2005","unstructured":"Stergianou K, Fox C, Russell NH. Fusion of NUP214 to ABL1 on amplified episomes in T-ALL--implications for treatment. Leukemia. 2005;19:1680\u20131.","journal-title":"Leukemia"},{"key":"378_CR67","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/gcc.20743","volume":"49","author":"A Hagemeijer","year":"2010","unstructured":"Hagemeijer A, Graux C. ABL1 rearrangements in T-cell acute lymphoblastic leukemia. Genes Chromosomes Cancer. 2010;49:299\u2013308.","journal-title":"Genes Chromosomes Cancer"},{"key":"378_CR68","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1200\/JCO.2011.40.3907","volume":"30","author":"AV Moorman","year":"2012","unstructured":"Moorman AV, Schwab C, Ensor H, Russell LJ, Morrison H, Jones L, et al. IGH translocations, CRLF2 deregulation, and microdeletions in adolescents and adults with acute lymphoblastic leukemia. J Clin Oncol. 2012;30:3100\u20138.","journal-title":"J Clin Oncol"},{"key":"378_CR69","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.beha.2011.09.004","volume":"24","author":"GC Mullighan","year":"2011","unstructured":"Mullighan GC. Genomic profiling of B-progenitor acute lymphoblastic leukemia. Best Pract Res Clin Hematol. 2011;24:489\u2013503.","journal-title":"Best Pract Res Clin Hematol"},{"key":"378_CR70","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1053\/j.seminhematol.2013.10.001","volume":"50","author":"GC Mullighan","year":"2013","unstructured":"Mullighan GC. Genomic characterisation of childhood lymphoblastic leukemia. Semin Hematol. 2013;50:314\u201324.","journal-title":"Semin Hematol"},{"key":"378_CR71","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","volume":"131","author":"M Hallek","year":"2018","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131:2745\u201360.","journal-title":"Blood"},{"key":"378_CR72","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","volume":"370","author":"R Furman","year":"2014","unstructured":"Furman R, Sharman J, Coutre S, Cheson B, Pagel J, Hillmen P, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370:997\u20131007.","journal-title":"N Engl J Med"},{"key":"378_CR73","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1182\/blood-2014-10-606038","volume":"125","author":"JC Byrd","year":"2015","unstructured":"Byrd JC, Furman RR, Coutre SE, Burger JA, Blum KA, Coleman M, et al. Three-year follow-up of treatment-na\u00efve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015;125:2497\u2013506.","journal-title":"Blood"},{"key":"378_CR74","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1470-2045(14)71182-9","volume":"16","author":"M Farooqui","year":"2015","unstructured":"Farooqui M, Valdez J, Martyr S, Aue G, Saba N, Niemann CU, et al. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Lancet Oncol. 2015;16:169\u201376.","journal-title":"Lancet Oncol"},{"key":"378_CR75","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/s41375-017-0007-7","volume":"32","author":"J Malcikova","year":"2018","unstructured":"Malcikova J, Tausch E, Rossi D, Sutton LA, Soussi T, Zenz T, et al. ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia - update on methodological approaches and results interpretation. Leukemia. 2018;32:1070\u201380.","journal-title":"Leukemia"},{"key":"378_CR76","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/leu.2017.125","volume":"31","author":"R Rosenquist","year":"2017","unstructured":"Rosenquist R, Ghia P, Hadzidimitriou A, Sutton L-A, Agathangelidis A, Baliakas P, et al. Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: updated ERIC recommendations. Leukemia. 2017;31:1477\u201381.","journal-title":"Leukemia"},{"key":"378_CR77","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1182\/blood-2010-12-327858","volume":"118","author":"P Ouillette","year":"2011","unstructured":"Ouillette P, Collins R, Shakhan S, Li J, Peres E, Kujawski L, et al. Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia. Blood. 2011;118:3051\u201361.","journal-title":"Blood"},{"key":"378_CR78","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jmoldx.2012.09.006","volume":"15","author":"CD Schweighofer","year":"2013","unstructured":"Schweighofer CD, Coombes KR, Majewski T, Barron LL, Lerner S, Sargent RL, et al. Genomic variation by whole-genome SNP mapping arrays predicts time-to-event outcome in patients with chronic lymphocytic leukemia: a comparison of CLL and HapMap genotypes. J Mol Diagn. 2013;15:196\u2013209.","journal-title":"J Mol Diagn"},{"key":"378_CR79","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1182\/blood-2016-01-691550","volume":"128","author":"CD Herling","year":"2016","unstructured":"Herling CD, Klaum\u00fcnzer M, Rocha CK, Altm\u00fcller J, Thiele H, Bahlo J, et al. Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy. Blood. 2016;128:395\u2013404.","journal-title":"Blood"},{"key":"378_CR80","doi-asserted-by":"crossref","first-page":"54297","DOI":"10.18632\/oncotarget.17350","volume":"8","author":"A Puiggros","year":"2017","unstructured":"Puiggros A, Collado R, Calasanz MJ, Ortega M, Ruiz-Xivill\u00e9 N, Rivas-Delgado A, et al. Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53\/ATM FISH deletions. Oncotarget. 2017;8:54297\u2013303.","journal-title":"Oncotarget"},{"key":"378_CR81","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1038\/onc.2012.411","volume":"32","author":"SN Malek","year":"2013","unstructured":"Malek SN. The biology and clinical significance of acquired genomic copy number aberrations and recurrent gene mutations in chronic lymphocytic leukemia. Oncogene. 2013;32:2805\u201317.","journal-title":"Oncogene"},{"key":"378_CR82","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","volume":"127","author":"P Sonneveld","year":"2016","unstructured":"Sonneveld P, Avet-Loiseau H, Lonial S, Usami S, Siegel D, Anderson KC, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016;127:2955\u201362.","journal-title":"Blood"},{"key":"378_CR83","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.3324\/haematol.2018.189159","volume":"103","author":"J Caers","year":"2018","unstructured":"Caers J, Garderet L, Kort\u00fcm KM, O\u2019Dwyer ME, van de Donk NWCJ, Binder M, et al. European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when. Haematologica. 2018;103:1772\u201384.","journal-title":"Haematologica"},{"key":"378_CR84","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/leu.2011.204","volume":"26","author":"KD Boyd","year":"2012","unstructured":"Boyd KD, Ross FM, Chiecchio L, Dagrada G, Konn ZJ, Tapper WJ, et al. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia. 2012;26:349\u201355.","journal-title":"Leukemia"},{"key":"378_CR85","unstructured":"NICE guidelines Myeloma: diagnosis and management. National Institute for Health and Care Excellence. 2016. https:\/\/www.nice.org.uk\/guidance\/ng35 ."},{"key":"378_CR86","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/sj.leu.2403586","volume":"19","author":"S Wuilleme","year":"2005","unstructured":"Wuilleme S, Robillard N, Lod\u00e9 L, Magrangeas F, Beris H, Harousseau JL, et al. Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma. Leukemia. 2005;19:275\u20138.","journal-title":"Leukemia"},{"key":"378_CR87","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.3324\/haematol.2011.056176","volume":"97","author":"F Ross","year":"2012","unstructured":"Ross F, Avet-Loiseau H, Ameye G, Guti\u00e9rrez NC, Liebisch P, O\u2019Connor S, et al. Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders. Haematologica. 2012;97:1272\u20137.","journal-title":"Haematologica"},{"key":"378_CR88","unstructured":"Parker A, Bain B, Devereux S, Gatter K, Jack A, Matutes E, et al. Best practice in lymphoma diagnosis and reporting. 2008. www.rcpath.org"},{"key":"378_CR89","unstructured":"WHO classification of tumours of haematopoietic and lymphoid tissues. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, et al. editors. 4th Ed. Lyon: IARC Press; 2008."},{"key":"378_CR90","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/ejhg.2013.125","volume":"22","author":"M Claustres","year":"2014","unstructured":"Claustres M, Ko\u017eich V, Dequeker E, Fowler B, Hehir-Kwa JY, Miller K, et al. European Society of Human Genetics. Recommendations for reporting results of diagnostic genetic testing (biochemical, cytogenetic and molecular genetic). Eur J Hum Genet. 2014;22:160\u201370.","journal-title":"Eur J Hum Genet"},{"key":"378_CR91","first-page":"1143","volume":"57","author":"M Guttenbach","year":"1995","unstructured":"Guttenbach M, Koschorz B, Bernthaler U, Grimm T, Schmid M. Sex chromosome loss and aging: in situ hybridisation studies on human interphase nuclei. Am J Hum Genet. 1995;57:1143\u201350.","journal-title":"Am J Hum Genet"},{"key":"378_CR92","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/(SICI)1098-2264(200001)27:1<11::AID-GCC2>3.0.CO;2-I","volume":"27","author":"A Wiktor","year":"2000","unstructured":"Wiktor A, Rybicki BA, Piao ZS, Shurafa M, Maeda K, et al. Cinical significance of Y loss in hematologic disease. Genes Chromosomes Cancer. 2000;27:11\u201316.","journal-title":"Genes Chromosomes Cancer"},{"key":"378_CR93","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.leukres.2014.11.005","volume":"39","author":"RS Goswami","year":"2015","unstructured":"Goswami RS, Liang CS, Beuso-Ramos CE, Hu S, Goswani C, Yon C, et al. Isolated+15 in bone marrow: disease- associated or a benign finding? Leuk Res. 2015;39:72\u201376.","journal-title":"Leuk Res"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41375-019-0378-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-019-0378-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-019-0378-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T11:33:52Z","timestamp":1720956832000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-019-0378-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,29]]},"references-count":93,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["378"],"URL":"https:\/\/doi.org\/10.1038\/s41375-019-0378-z","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,29]]},"assertion":[{"value":"25 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}